This review summarises important pharmacological and clinical characteristics of treatment with pomalidomide, an oral medication taken in capsule form.
Pomalidomide, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.
Independent commentary has been provided by Associate Professor Hang Quach of the University of Melbourne and Director of Clinical Haematology and Clinical Haematology Research at St. Vincent’s Hospital Melbourne.
Please login below to download this issue (PDF)